Targeting glucose-dependent insulinotropic polypeptide receptor (GIPR) has emerged as a promising strategy against obesity and related diseases through the “incretin effect” and regulation of other biological processes.

Empowered by the comprehensive abilities of Chemistry42, Insilico nominates ISM0676, the novel, oral available GIPR antagonist, as a clinical candidate compound (PCC) with both monotherapy and combination potential. The process from project initiation to PCC took 14 months, with less than 200 molecules synthesized and tested.

Preclinical studies have highlighted up to 31.3% body weight loss in diet-induced obese (DIO) humanized GIPR mice when co-administered with semaglutide. ISM0676 also demonstrated excellent in vivo metabolic stability, low drug-drug interaction risk, favorable safety profiles, and low predicted human efficacious dose, supporting future development.

Desire on the Couch is a thought-provoking exhibition coming to San Francisco January 28th. Co-organized by the California Institute of Integral Studies and the Kinsey Institute, the exhibition makes its debut during the American Psychoanalytic Association's annual meeting. Tracing a century-long struggle over how sexuality is measured, medicalized, and experienced, visitors are invited to explore rarely-seen letters, photographs, and archival materials that reveal how ideas about sexuality and desire have long been argued over, resisted, and reimagined.